First test of gene therapy for rare form of autism is underwaynews2026-02-23T14:00:16+00:00February 23rd, 2026|Endpoints News|
NeuExcell Therapeutics’ brain cancer therapy tests debated fieldnews2026-02-18T12:00:07+00:00February 18th, 2026|Endpoints News|
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapynews2026-02-17T11:03:37+00:00February 17th, 2026|Endpoints News|
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisitionnews2026-02-09T15:25:12+00:00February 9th, 2026|Endpoints News|
China startup AccurEdit raises $75M for gene editing therapiesnews2026-02-03T16:13:27+00:00February 3rd, 2026|Endpoints News|
Ultragenyx unwraps data that may be central to its gene therapy resubmissionnews2026-02-03T13:00:48+00:00February 3rd, 2026|Endpoints News|
Ultragenyx resubmits gene therapy for rare neuro disease to FDAnews2026-01-30T16:50:40+00:00January 30th, 2026|Endpoints News|
FDA suspends two Regenxbio gene therapy trials after patient developed brain tumornews2026-01-28T15:56:29+00:00January 28th, 2026|Endpoints News|
Cellares raises $257M to fund global expansion as it eyes 2027 IPOnews2026-01-28T12:00:48+00:00January 28th, 2026|Endpoints News|
Lilly partners with recombinase-based gene editing startup Seamless Therapeuticsnews2026-01-28T12:00:19+00:00January 28th, 2026|Endpoints News|
